Literature DB >> 6197277

Central somatosensory conduction time and short latency somatosensory evoked potentials in post-traumatic coma.

E Rumpl, M Prugger, F Gerstenbrand, J M Hackl, A Pallua.   

Abstract

Short latency evoked potentials (SEPs) were elicited by stimulation of the median nerve at the wrist and recorded simultaneously from the neck and the contralateral scalp in 44 comatose patients with signs of brain stem impairment due to head injury. Thirty-four patients were studied in acute coma on day 1 or 2 after brain injury. Twenty-three patients were studied in prolonged coma during days 3-12 after trauma. Six patients were examined in brain death. Brain stem involvement was divided clinically and by CT scan into secondary lesions due to supratentorial mass displacement and primary lesions due to direct violence to the brain stem. The central somatosensory conduction time (CCT) was measured by subtracting the peak latency of the major response from the neck (N14) from that of the primary scalp response (N20). The amplitude ratios (ARs) N20/N14 were calculated for each trace. Further asymmetries and absence of SEP over one or both hemispheres were noted. In cases in coma due to supratentorial lesions CCT and AR were close to normal in patients with good outcome. CCT increased and AR decreased with the worsening of outcome both in acute and prolonged coma. Asymmetries of SEPs indicated moderate or severe final disability. Patients with absent SEPs over one or both hemispheres due to supratentorial lesions died or survived severely disabled (1 case). In patients suffering from primary brain stem dysfunction, confirmed by a normal or slightly abnormal CT scan, prolonged CCT, asymmetric but also absent SEPs were also found in patients with good outcome both in acute and prolonged coma. AR was generally low in these cases. Early appearance of SEPs or early recovery of initially distorted SEPs and decrease of CCT in prolonged coma or during recovery was a favourable prognostic sign. Therefore even absent or severely distorted SEPs should be interpreted cautiously in patients who may suffer from primary brain stem involvement. Scalp SEPs were totally absent in patients with brain death.

Entities:  

Mesh:

Year:  1983        PMID: 6197277     DOI: 10.1016/0013-4694(83)90026-3

Source DB:  PubMed          Journal:  Electroencephalogr Clin Neurophysiol        ISSN: 0013-4694


  8 in total

Review 1.  Are somatosensory evoked potentials the best predictor of outcome after severe brain injury? A systematic review.

Authors:  B G Carter; W Butt
Journal:  Intensive Care Med       Date:  2005-04-22       Impact factor: 17.440

2.  Neuromonitoring.

Authors:  W Hacke
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

3.  Prognostic value of somatosensory- and motor-evoked potentials in patients with a non-traumatic coma.

Authors:  J Zentner; A Ebner
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988

4.  Evoked potentials in post-traumatic coma.

Authors:  M Lorenz; M R Gaab
Journal:  Neurosurg Rev       Date:  1989       Impact factor: 3.042

Review 5.  Prognostic value of somatosensory evoked potentials in comatose children: a systematic literature review.

Authors:  Riccardo Carrai; Antonello Grippo; Silvia Lori; Francesco Pinto; Aldo Amantini
Journal:  Intensive Care Med       Date:  2010-04-27       Impact factor: 17.440

Review 6.  [Coma. The prognostic value of evoked potentials in patients after traumatic brain injury].

Authors:  M H Morgalla; J Bauer; R Ritz; M Tatagiba
Journal:  Anaesthesist       Date:  2006-07       Impact factor: 1.041

Review 7.  Multimodality evoked potentials and early prognosis in comatose patients.

Authors:  R Firsching; R A Frowein
Journal:  Neurosurg Rev       Date:  1990       Impact factor: 3.042

8.  Spatial mapping of SEP in comatose patients: improved outcome prediction by combined parietal N20 and frontal N30 analysis.

Authors:  E Facco; M Munari; B Donà; F Baratto; D Fiore; A U Behr; G Giron
Journal:  Brain Topogr       Date:  1991       Impact factor: 3.020

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.